Trials / Completed
CompletedNCT04799873
Alpha-1-Antitrypsin-Deficiency in COVID-19
Individual Treatment of COVID-19 by Application of Alpha-1-antitrypsin
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (actual)
- Sponsor
- Universität des Saarlandes · Academic / Other
- Sex
- All
- Age
- 18 Years – 110 Years
- Healthy volunteers
- Not accepted
Summary
The blood concentrations of alpha-1-antitrypsin are monitored during COVID-19. The clinical course of patients that received AAT infusion for clinical indication is monitored.
Detailed description
The blood concentrations of alpha-1-antitrypsin are monitored during COVID-19. The clinical course of patients that received AAT infusion for clinical indication is monitored. Clinical outcomes, blood inflammatory markers, and virus load are monitored.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AAT( Alpha 1 Antitrypsin) | AAT administration based on clinical indication |
Timeline
- Start date
- 2020-04-08
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
- First posted
- 2021-03-16
- Last updated
- 2025-05-25
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04799873. Inclusion in this directory is not an endorsement.